Literature DB >> 20430789

Colistin susceptibility testing: evaluation of reliability for cystic fibrosis isolates of Pseudomonas aeruginosa and Stenotrophomonas maltophilia.

Samuel M Moskowitz1, Elizabeth Garber, Yunhua Chen, Sarah A Clock, Setareh Tabibi, Amanda K Miller, Michael Doctor, Lisa Saiman.   

Abstract

OBJECTIVES: Antibiotic susceptibility methods that are commonly used to test bacterial isolates from patients with cystic fibrosis are of uncertain reliability for the polymyxins. To assess the reliability of four standard testing methods, this pilot study used a challenge set that included polymyxin-resistant isolates of Pseudomonas aeruginosa and Stenotrophomonas maltophilia.
METHODS: Twenty-five P. aeruginosa and 12 S. maltophilia isolates were tested for susceptibility to colistin (polymyxin E). Repeatability (concordance of replicates performed concurrently), reproducibility (concordance of replicates performed over time) and comparability (concordance of different methods) of agar dilution, broth microdilution, Etest and disc diffusion were assessed through the use of descriptive statistics and scatterplot analyses.
RESULTS: All four methods displayed excellent repeatability (overall concordance rate of 99%). However, analysis of reproducibility revealed substantially lower rates of concordance (74% for agar dilution, 84% for broth microdilution and Etest, and 91% for disc diffusion). In addition, comparability to agar dilution of the three other methods was generally poor, with overall rates of very major error ranging from 12% for broth microdilution to 18% for Etest and disc diffusion.
CONCLUSIONS: Compared with agar dilution, other susceptibility testing methods give high rates of apparent false polymyxin susceptibility for cystic fibrosis isolates of P. aeruginosa and S. maltophilia. Prospective study of the correlation between in vitro susceptibility and clinical response is needed to clarify whether these discrepancies reflect oversensitivity of the agar dilution method or insensitivity of the other methods.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20430789      PMCID: PMC2882871          DOI: 10.1093/jac/dkq131

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  31 in total

1.  In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis.

Authors:  J Li; J Turnidge; R Milne; R L Nation; K Coulthard
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

2.  In vitro activity of the aerosolized agents colistin and tobramycin and five intravenous agents against Pseudomonas aeruginosa isolated from cystic fibrosis patients in southwestern Germany.

Authors:  Tanja Schülin
Journal:  J Antimicrob Chemother       Date:  2002-02       Impact factor: 5.790

3.  Comparison of agar diffusion methodologies for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients.

Authors:  J L Burns; L Saiman; S Whittier; D Larone; J Krzewinski; Z Liu; S A Marshall; R N Jones
Journal:  J Clin Microbiol       Date:  2000-05       Impact factor: 5.948

4.  Transmission of colistin-resistant Pseudomonas aeruginosa between patients attending a pediatric cystic fibrosis center.

Authors:  M Denton; K Kerr; L Mooney; V Keer; A Rajgopal; K Brownlee; P Arundel; S Conway
Journal:  Pediatr Pulmonol       Date:  2002-10

5.  In vitro susceptibility of Stenotrophomonas maltophilia isolates: comparison of disc diffusion, Etest and agar dilution methods.

Authors:  A C Nicodemo; M R E Araujo; A S Ruiz; A C Gales
Journal:  J Antimicrob Chemother       Date:  2004-02-18       Impact factor: 5.790

6.  Cationic antimicrobial peptides activate a two-component regulatory system, PmrA-PmrB, that regulates resistance to polymyxin B and cationic antimicrobial peptides in Pseudomonas aeruginosa.

Authors:  Joseph B McPhee; Shawn Lewenza; Robert E W Hancock
Journal:  Mol Microbiol       Date:  2003-10       Impact factor: 3.501

7.  Survey of resistance of Pseudomonas aeruginosa from UK patients with cystic fibrosis to six commonly prescribed antimicrobial agents.

Authors:  T L Pitt; M Sparrow; M Warner; M Stefanidou
Journal:  Thorax       Date:  2003-09       Impact factor: 9.139

8.  PmrAB, a two-component regulatory system of Pseudomonas aeruginosa that modulates resistance to cationic antimicrobial peptides and addition of aminoarabinose to lipid A.

Authors:  Samuel M Moskowitz; Robert K Ernst; Samuel I Miller
Journal:  J Bacteriol       Date:  2004-01       Impact factor: 3.490

9.  Antimicrobial susceptibility and synergy studies of Stenotrophomonas maltophilia isolates from patients with cystic fibrosis.

Authors:  Pablo San Gabriel; Juyan Zhou; Setareh Tabibi; Yunhua Chen; Marco Trauzzi; Lisa Saiman
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

10.  Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis.

Authors:  Jian Li; Kingsley Coulthard; Robert Milne; Roger L Nation; Steven Conway; Daniel Peckham; Christine Etherington; John Turnidge
Journal:  J Antimicrob Chemother       Date:  2003-10-29       Impact factor: 5.790

View more
  17 in total

Review 1.  Antimicrobial Susceptibility Testing for Polymyxins: Challenges, Issues, and Recommendations.

Authors:  Fereshteh Ezadi; Abdollah Ardebili; Reza Mirnejad
Journal:  J Clin Microbiol       Date:  2019-03-28       Impact factor: 5.948

Review 2.  Polymyxins: Antibacterial Activity, Susceptibility Testing, and Resistance Mechanisms Encoded by Plasmids or Chromosomes.

Authors:  Laurent Poirel; Aurélie Jayol; Patrice Nordmann
Journal:  Clin Microbiol Rev       Date:  2017-04       Impact factor: 26.132

3.  Susceptibility Testing for the Polymyxins: Two Steps Back, Three Steps Forward?

Authors:  Shawn Vasoo
Journal:  J Clin Microbiol       Date:  2017-07-19       Impact factor: 5.948

4.  Colistin and Polymyxin B Susceptibility Testing for Carbapenem-Resistant and mcr-Positive Enterobacteriaceae: Comparison of Sensititre, MicroScan, Vitek 2, and Etest with Broth Microdilution.

Authors:  Ka Lip Chew; My-Van La; Raymond T P Lin; Jeanette W P Teo
Journal:  J Clin Microbiol       Date:  2017-06-07       Impact factor: 5.948

5.  Cation concentration variability of four distinct Mueller-Hinton agar brands influences polymyxin B susceptibility results.

Authors:  Raquel Girardello; Paulo J M Bispo; Tiago M Yamanaka; Ana C Gales
Journal:  J Clin Microbiol       Date:  2012-05-02       Impact factor: 5.948

6.  The Pseudomonas aeruginosa PhoP-PhoQ two-component regulatory system is induced upon interaction with epithelial cells and controls cytotoxicity and inflammation.

Authors:  Shaan L Gellatly; Brittany Needham; Laurence Madera; M Stephen Trent; Robert E W Hancock
Journal:  Infect Immun       Date:  2012-06-18       Impact factor: 3.441

Review 7.  Rescuing the Last-Line Polymyxins: Achievements and Challenges.

Authors:  Sue C Nang; Mohammad A K Azad; Tony Velkov; Qi Tony Zhou; Jian Li
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

8.  Comparison of the Vitek 2, MicroScan, and Etest methods with the agar dilution method in assessing colistin susceptibility of bloodstream isolates of Acinetobacter species from a Korean university hospital.

Authors:  Seung Yeob Lee; Jong Hee Shin; Kyungwon Lee; Min Young Joo; Kyung Hwa Park; Myung Geun Shin; Soon Pal Suh; Dong Wook Ryang; Soo Hyun Kim
Journal:  J Clin Microbiol       Date:  2013-03-27       Impact factor: 5.948

9.  Evaluation of colistin susceptibility in multidrug-resistant clinical isolates from cystic fibrosis, France.

Authors:  S Biswas; J-C Dubus; M Reynaud-Gaubert; N Stremler; J-M Rolain
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-05-30       Impact factor: 3.267

10.  Colistin MIC variability by method for contemporary clinical isolates of multidrug-resistant Gram-negative bacilli.

Authors:  Janet A Hindler; Romney M Humphries
Journal:  J Clin Microbiol       Date:  2013-03-13       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.